Carcinoma in situ of rectum
ICD-10 D01.2 is a billable code used to indicate a diagnosis of carcinoma in situ of rectum.
Carcinoma in situ of the rectum refers to a localized form of cancer where abnormal cells are present in the rectal mucosa but have not invaded deeper tissues or metastasized to other parts of the body. This condition is characterized by the presence of atypical cells that exhibit malignant features but remain confined to the site of origin. Early detection through screening methods such as colonoscopy is crucial, as it allows for timely intervention and management. The prognosis for patients diagnosed with carcinoma in situ is generally favorable, especially when detected early. Treatment options may include local excision, endoscopic resection, or surveillance protocols, depending on the extent of the lesion and patient factors. Regular follow-up is essential to monitor for any signs of progression to invasive cancer, which can occur if left untreated. Surveillance protocols typically involve periodic colonoscopy and imaging studies to ensure that any changes in the rectal tissue are promptly addressed.
Detailed pathology reports, treatment plans, and follow-up notes.
Patients presenting with rectal bleeding, abnormal findings on colonoscopy, or routine surveillance for high-risk patients.
Ensure accurate staging and documentation of any co-existing gastrointestinal conditions.
Comprehensive treatment history, including surgical notes and pathology findings.
Management of patients post-excision of rectal carcinoma in situ and monitoring for recurrence.
Coordination with pathology for accurate coding of histological findings.
Used when a biopsy confirms carcinoma in situ and excision is performed.
Pathology report confirming carcinoma in situ and operative notes detailing the procedure.
Gastroenterologists must ensure accurate coding based on findings during the procedure.
The prognosis for carcinoma in situ of the rectum is generally favorable, especially with early detection and appropriate management. Regular surveillance is crucial to monitor for any progression to invasive cancer.
